Who are OraVerse Injectable Product's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fexofenadine HCL and pseudoephedrine HCL, Phentolamine Ophthalmic Solution 0.75%, Phentolamine Opthalmic Solution 0.75%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oraverse-injectable-product.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

OraVerse Injectable Product — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

OraVerse Injectable Product (OraVerse Injectable Product) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-adrenergic antagonist. Area: Dental/Local Anesthesia.

phase 3 Alpha-adrenergic antagonist Alpha-1 and alpha-2 adrenergic receptors Dental/Local Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

OraVerse Injectable Product (OraVerse Injectable Product) — sara nabil. OraVerse is a phentolamine mesylate injectable that reverses the effects of local anesthetic vasoconstrictors by blocking alpha-adrenergic receptors.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
OraVerse Injectable Product TARGET	OraVerse Injectable Product	sara nabil	phase 3	Alpha-adrenergic antagonist	Alpha-1 and alpha-2 adrenergic receptors
Fexofenadine HCL and pseudoephedrine HCL	Fexofenadine HCL and pseudoephedrine HCL	Sanofi	marketed	Antihistamine and decongestant combination	H1 receptor (fexofenadine); alpha-1 and alpha-2 adrenergic receptors (pseudoephedrine)
Phentolamine Ophthalmic Solution 0.75%	Phentolamine Ophthalmic Solution 0.75%	Ocuphire Pharma, Inc.	phase 3	Alpha-adrenergic antagonist	Alpha-1 and alpha-2 adrenergic receptors
Phentolamine Opthalmic Solution 0.75%	Phentolamine Opthalmic Solution 0.75%	Ocuphire Pharma, Inc.	phase 3	Alpha-adrenergic antagonist	Alpha-1 adrenergic receptor, Alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-adrenergic antagonist class)

Ocuphire Pharma, Inc. · 2 drugs in this class
sara nabil · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OraVerse Injectable Product — Competitive Intelligence Brief. https://druglandscape.com/ci/oraverse-injectable-product. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing